Letter to the editor: radiomics analysis for predicting pembrolizumab response in patients with advanced rare cancers

A commentary on the original research article: ‘Radiomics analysis for predicting pembrolizumab response in patients with advanced rare cancers’. Of note, the predictor selection process, the cross-validation method, along with the lack of final testing of the developed model with a separated data s...

Descripción completa

Detalles Bibliográficos
Autores principales: Cunha, Mateus Trinconi, Carvalho, Vinicius Jardim, Loureiro, Rafael Maffei, Brantis-de-Carvalho, Carlos Eduardo, Cintra, Murilo Bicudo, de Castro Junior, Gilberto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8317071/
https://www.ncbi.nlm.nih.gov/pubmed/34315822
http://dx.doi.org/10.1136/jitc-2021-003044
_version_ 1783729998718304256
author Cunha, Mateus Trinconi
Carvalho, Vinicius Jardim
Loureiro, Rafael Maffei
Brantis-de-Carvalho, Carlos Eduardo
Cintra, Murilo Bicudo
de Castro Junior, Gilberto
author_facet Cunha, Mateus Trinconi
Carvalho, Vinicius Jardim
Loureiro, Rafael Maffei
Brantis-de-Carvalho, Carlos Eduardo
Cintra, Murilo Bicudo
de Castro Junior, Gilberto
author_sort Cunha, Mateus Trinconi
collection PubMed
description A commentary on the original research article: ‘Radiomics analysis for predicting pembrolizumab response in patients with advanced rare cancers’. Of note, the predictor selection process, the cross-validation method, along with the lack of final testing of the developed model with a separated data set may mask overfitting, overestimating performance metrics.
format Online
Article
Text
id pubmed-8317071
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-83170712021-08-13 Letter to the editor: radiomics analysis for predicting pembrolizumab response in patients with advanced rare cancers Cunha, Mateus Trinconi Carvalho, Vinicius Jardim Loureiro, Rafael Maffei Brantis-de-Carvalho, Carlos Eduardo Cintra, Murilo Bicudo de Castro Junior, Gilberto J Immunother Cancer Commentary A commentary on the original research article: ‘Radiomics analysis for predicting pembrolizumab response in patients with advanced rare cancers’. Of note, the predictor selection process, the cross-validation method, along with the lack of final testing of the developed model with a separated data set may mask overfitting, overestimating performance metrics. BMJ Publishing Group 2021-07-27 /pmc/articles/PMC8317071/ /pubmed/34315822 http://dx.doi.org/10.1136/jitc-2021-003044 Text en © Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Commentary
Cunha, Mateus Trinconi
Carvalho, Vinicius Jardim
Loureiro, Rafael Maffei
Brantis-de-Carvalho, Carlos Eduardo
Cintra, Murilo Bicudo
de Castro Junior, Gilberto
Letter to the editor: radiomics analysis for predicting pembrolizumab response in patients with advanced rare cancers
title Letter to the editor: radiomics analysis for predicting pembrolizumab response in patients with advanced rare cancers
title_full Letter to the editor: radiomics analysis for predicting pembrolizumab response in patients with advanced rare cancers
title_fullStr Letter to the editor: radiomics analysis for predicting pembrolizumab response in patients with advanced rare cancers
title_full_unstemmed Letter to the editor: radiomics analysis for predicting pembrolizumab response in patients with advanced rare cancers
title_short Letter to the editor: radiomics analysis for predicting pembrolizumab response in patients with advanced rare cancers
title_sort letter to the editor: radiomics analysis for predicting pembrolizumab response in patients with advanced rare cancers
topic Commentary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8317071/
https://www.ncbi.nlm.nih.gov/pubmed/34315822
http://dx.doi.org/10.1136/jitc-2021-003044
work_keys_str_mv AT cunhamateustrinconi lettertotheeditorradiomicsanalysisforpredictingpembrolizumabresponseinpatientswithadvancedrarecancers
AT carvalhoviniciusjardim lettertotheeditorradiomicsanalysisforpredictingpembrolizumabresponseinpatientswithadvancedrarecancers
AT loureirorafaelmaffei lettertotheeditorradiomicsanalysisforpredictingpembrolizumabresponseinpatientswithadvancedrarecancers
AT brantisdecarvalhocarloseduardo lettertotheeditorradiomicsanalysisforpredictingpembrolizumabresponseinpatientswithadvancedrarecancers
AT cintramurilobicudo lettertotheeditorradiomicsanalysisforpredictingpembrolizumabresponseinpatientswithadvancedrarecancers
AT decastrojuniorgilberto lettertotheeditorradiomicsanalysisforpredictingpembrolizumabresponseinpatientswithadvancedrarecancers

Ejemplares similares